We next compared the ability of NME2 TR and MYC pathway to predict Enzalutamide resistance in Abida et al. cohort33, with the predictive ability of known markers of prostate cancer (i) aggressiveness, (ii) response to first-generation ADT and ARSIs (not specific to any particular drug), and (iii) Enzalutamide-specific response (Fig. 6). This evidence concerns the gene NME2 and prostate carcinoma.